NFKB1 and plasma cell myeloma: Bortezomib—The proteasome inhibitor bortezomib, known for its use in multiple myeloma treatment [80], prevents IκBα degradation, thereby blocking NF-κB nuclear translocation and, consequently, its transcriptional activity [81].